Charles LeVea, MD, PhD

PrintE-mail
Assistant Professor, Department of Pathology
Director of Surgical Pathology
Fellowship Director, Oncologic Surgical Pathology
Roswell Park Cancer Institute
Assistant Professor of Pathology and Anatomical Sciences
School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise: 
Colon cancer
Rectal cancer

Research

Research Interests: 
Signaling pathways involved in upper and lower gastrointestinal cancers
Gastrointestinal Pathology Disease Site Research Group

Background Information

Education and Training: 
MD - State University of New York at Stony Brook
PhD - University of Pennsylvania, Philadelphia, PA
MS - University of Rochester, Rochester, NY
Residency: 
University of Rochester, Rochester, NY
Board Certification: 
Anatomic Pathology, American Board of Pathology
Clinical Pathology, American Board of Pathology
Fellowships: 
University of Rochester, Rochester, NY

Publications

Publications: 
  • Iyer RV, Fakih M, Ma W, Tucker C, Levea C, Starostik P, Litwin A, Tan W, Khushalani NI, Adjei AA. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G) : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract# 258
  • Bharthuar A, Pearce L, Litwin A, LeVea C, Kuvshinoff B, Iyer R. Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report. JOP : Journal of the pancreas 2009; 10(5):523-527
  • Bir AS, Fora AA, Levea C, Fakih MG. Spontaneous regression of colorectal cancer metastatic to retroperitoneal lymph nodes. Anticancer research 2009; 29(2):465-468
  • Chadha MK, Litwin A, Levea C, Iyer R, Yang G, Javle M, Gibbs JF. Surgical resection after TNFerade therapy for locally advanced pancreatic cancer. JOP : Journal of the pancreas 2009; 10(5):535-538
  • Javle MM, Smith PF, Prey JD, Clark KR, LeVea C, Nava HR, Schiff MD, Vinjamaram S, O'Malley L, Wilding GE, Nwogu CE, Yang G, Pendyala L. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer investigation 2009; 27(2):193-200
  • Jing W, Gibson NW, Keane DM, Sun F-L, LeVea C, Brattain L, Sharatt EA, Dominiquez I, Beko A, Hauser J, Kuropatwinski K, Xiao-Qiong L, Rose R, Kan JLC, Rajput A, Brattain MG. Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. Journal of biological chemistry 2009; 284(16):10912-10922
  • Ongchin M, Sharratt E, Dominguez I, Simms N, Wang J, Cheney R, LeVea C, Brattain M, Rajput A. The effects of epidermal growth factor receptor activation and attenuation of the TGFbeta pathway in an orthotopic model of colon cancer. Journal of surgical research 2009; 156(2):250-256
  • Iyer R, Javle M, Robins M, Levea C, Litwin A, Nava H, Tan W, Shefter T, Yang G, Khushalani NI. Phase II multicenter study of erlotinib and radiation therapy (RT) for elderly patients (PTS) with esophageal carcinoma (EC)- final report. Annals of oncology 2010; 21(Suppl. 8):259-260
  • Khushalani NI, Brady W, Fetterly G, Prey J, Levea C, Litwin A, Grande C, Iyer R, Javle M. Continuous and intermittent vorinostat (V) in combination with folfiri in advanced upper gastrointestinal cancer (AUGC): Preliminary results of a phase I pharmacokinetic (PK) study. Annals of oncology 2010; 21(Suppl. 8):260
  • Guo R, Chen F, Paterson J, Lynch J, Sands A, Morrison C, LeVea C. Most Metastatic Colorectal Adenocarcinomas Express Less CDX2 Than Their Primaries. Laboratory investigation 2011; 91(Suppl. 1):630
  • Fakih MG, Park YM, Puthillath A, Levea C, Ross ME, Rustum YM, Andrews C, Toth K, Pendyala L, Yang GY, Bullarddunn K, Rajput A. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. International journal of radiation oncology, biology, physics 2008; 72(3):650-657
  • Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H, Nwogu C. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. American journal of clinical oncology 2008; 31(4):329-334
  • Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, Fakih MG. Significance of signet-ring cells in patients with colorectal cancer. Diseases of the colon and rectum 2008; 51(1):50-55
  • Rajput A, Brattain MG, Hoffman RM, Mazurchuk R, Sharratt E, Levea C, Beko A, Rose R, Dominguez San Martin I, Wang J. Characterization of HCT116 human colon cancer cells in an orthotopic model. Journal of surgical research 2008; 147(2):276-281
  • Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. CD24 expression is an independent prognostic marker in cholangiocarcinoma. Journal of gastrointestinal surgery 2007; 11(4):445-451
  • Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Annals of surgical oncology 2007; 14(2):752-758
  • Guo XN, Brattain MG, Hoffman RM, LeVea C, Kuropatwinski K, Beko A, Hauser J, Rose R, Rajput A, Wang J. Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. Cancer research 2007; 67(12):5851-5858
  • Gupta B, LeVea C, Litwin A, Fakih MG. Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. Clinical colorectal cancer 2007; 6(6):447-449
  • Pande AU, Iyer RV, Rani A, Maddipatla S, Yang GY, Nwogu CE, Black JD, Levea CM, Javle MM. Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology 2007; 73(5-6):281-289
  • Teng BP, Heffler MD, Lai EC, Zhao Y-L, LeVea CM, Golubovskaya VM, BullardDunn KM. Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth by increasing apoptosis. Anti-cancer agents in medicinal chemistry 2011; 11(7):620-628
  • Iyer RV, Yang G, Schefter TE, Tan W, Nava HR, Levea C, Litwin A, Robins M, Khushalani NI. Phase II multicenter study of erlotinib with radiation therapy (RT) for elderly patients (pts) with esophageal carcinoma (EC): Final report : 2011 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2011; 29(4 Suppl.):135
  • Agrawal S, Kuvshmoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. CD24 expression is an independent prognostic marker in cholangiocarcinoma. Annals of surgical oncology 2007; 14(2 Suppl.):57
  • Dominguez I, Wang J, Levea C, Rose R, Sharratt E, Brattain M, Rajput A. Inhibition of apoptosis leads to a metastatic phenotype in an orthotopic model of colon. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:1297-1298
  • Fetterly GJ, Brady WE, LeVea CM, Litwin AM, Zagst PD, Prey JD, Tarquini M, Giardina MK, Iyer RV, Khushalani NI. A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15540
  • Iyer R, Khushalani N, Tan W, Litwin A, LeVea C, Hutson A, Tucker C, Ma W, Fakih M, Adjei A. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G). European journal of cancer (Oxford, England : 1990) 2009; 7(2):391
  • Juo XN, Raiput A, Rose R, Hauser J, Beko A, Kuropatwinski K, Levea C, Hoffman RM, Brattain MG, Wang J. Mutant PIK3CA bearing colon cancer cells display increased metastasis in an orthotopic model. Molecular cancer therapeutics 2007; 6(12 Part 2):3533S-3534S
  • Ongchin M, Sharratt E, Dominguez I, Wang J, Levea C, Brattain M, Rajput A. The characterization of PI3K mutations in an orthotopic model of colon cancer. Journal of the American College of Surgeons 2009; 209(3 Suppl.):S121-S122
  • Rani A, Javle MM, Levea CM, Yu J, Brattain M, Black JD, Sitrin M. EGFR, p-Erk and p-AKT expression in Barrett's Esophagus (BE): A prospective pilot study. American journal of gastroenterology 2007; 102(Suppl. 2):S138 (Abstract #58)
  • Sunga AY, Levea C, Fakih M, Reid M, Mahoney M, Smith J, Trump D, Johnson C, Schiff M. Aberrant crypt foci characterization in selected colorectal cancer risk groups. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:397
  • Alexiev BA, Levea CM. Nephrogenic adenoma of the urinary tract: a review. International journal of surgical pathology 2012; 20(2):123-131
  • Nurkin S, Nava HR, Yendamuri S, Levea CM, Nwogu C, Wilding G, Khushalani N. Outcomes of Endoscopic Resection for High Grade Dysplasia and Esophageal Cancer. Gastrointestinal endoscopy 2012; 75(4 Suppl.):473